An Experts’ Forum in Tokyo and Singapore on DDR and PARP inhibition
An Experts’ Forum in Tokyo and Singapore on DDR and PARP inhibition
Prof. Keiichi Fujiwara, Prof. Simon Boulton, Dr. Shinji Ohno, Dr. Rebecca Dent, Prof. Charlie Gourley
DDR and PARPi Expert Forums were held with international faculty in Tokyo and Singapore during January 2020.
Prof. Keiichi Fujiwara
Gynaecologic Oncologist
Saitama Medical University International Medical Center
Japan
Prof. Simon Boulton
Senior Scientist
Francis Crick Institute
United Kingdom (UK)
Dr. Shinji Ohno
Medical Oncologist
Cancer Institute Hospital of JFCR
Japan
Dr. Rebecca Dent
Medical Oncologist
National Cancer Center Singapore
Singapore
Prof. Charlie Gourley
Medical Oncologist
CRUK Edinburgh Centre, Nicola Murray Centre for Ovarian Cancer Re...
United Kingdom (UK)
Prof. Keiichi Fujiwara
Gynaecologic Oncologist
Saitama Medical University International Medical Center
Japan
Prof. Keiichi Fujiwara has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Prof. Simon Boulton
Senior Scientist
Francis Crick Institute
United Kingdom (UK)
Prof. Simon Boulton has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Dr. Shinji Ohno
Medical Oncologist
Cancer Institute Hospital of JFCR
Japan
Dr. Shinji Ohno has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Dr. Rebecca Dent
Medical Oncologist
National Cancer Center Singapore
Singapore
Dr. Rebecca Dent has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Prof. Charlie Gourley
Medical Oncologist
CRUK Edinburgh Centre, Nicola Murray Centre for Ovarian Cancer Research
United Kingdom (UK)
Prof. Charlie Gourley has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
| 60 min | Jan 2020
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
Learn about the role of PARP inhibitors in clinical practice and targeting DDR, including:
-
Mechanism of Action of PARP inhibition and targeting DDR
-
Clinical profile of PARP inhibitors and their benefit in ovarian and breast cancer
-
Appropriate patient selection for PARP inhibition
-
Future DDR and PARP inhibition